Janssen in MM discovery deal
Janssen Biotech Inc. partnered with the Cancer Research Technology commercialization arm of Cancer Research UK and the Institute of Cancer Research to discover and develop inhibitors of an undisclosed protein on the unfolded protein response (UPR) pathway to treat multiple myeloma (MM). The partners will work together to identify candidates, and Janssen will provide undisclosed research funding. The Johnson & Johnson (NYSE:JNJ) subsidiary will be responsible for clinical development of any candidates. Cancer Research and the institute will be eligible for undisclosed milestones, plus royalties, from Janssen. The UPR pathway is often upregulated in cancers in response to the accumulation of unfolded proteins in the endoplasmic reticulum (ER), which can lead to cell death. ...